We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Liquidia targets more than $1 billion in 2027 net revenues as YUTREPIA adoption and market share rise.
YUTREPIA posted $170.4 million in Q2 net product sales, up 31% sequentially, with 5,000 patient starts.
Liquidia plans higher R&D spending and 10 studies across YUTREPIA and L606 over the next 12 months.
Liquidia Corporation (LQDA - Free Report) used its Q2 2026 earnings call to reinforce a forward message centered on YUTREPIA adoption, commercial expansion and a path to more than $1 billion in net revenue in 2027.
Management also emphasized a broader inhaled-treprostinil strategy, pairing cash generation with a larger clinical program for YUTREPIA and L606. The Q&A focused on patient growth, payer access, community penetration and patent litigation.
LQDA Sets a 2027 Revenue Marker
Chief executive officer (CEO) Roger Jeffs said Liquidia is on track for more than $1 billion in net revenues in 2027, setting a longer-term benchmark for the franchise.
Chief operating officer and chief financial officer Michael Kaseta said referrals and new patient starts have followed a linear trajectory since launch and expressed confidence that the company can maintain that pace.
For Q2, EPS of $0.74 topped the Zacks Consensus Estimate of $0.7, while revenues of $171.7 million exceeded the $165.2 million consensus. Michael Kaseta said profitability should continue growing even as investment rises.
Liquidia Corporation Price, Consensus and EPS Surprise
Roger Jeffs said YUTREPIA generated $170.4 million in Q2 net product sales, up 31% sequentially. As of July 31, Liquidia had about 5,900 unique patient prescriptions and more than 5,000 patient starts.
Jeffs added that the inhaled prostacyclin market grew from $573 million in Q1 to $607 million in Q2, while YUTREPIA approached 30% of that market on a net revenue basis.
The CEO tied the adoption to management's tolerability-dose-efficacy framework, arguing that higher tolerable dosing supports the company's confidence in continued uptake.
LQDA Broadens Commercial Reach
Chief commercial officer Scott Moomaw said the expanded sales force will increase contact with existing prescribers while pushing deeper into community settings, particularly for PH-ILD patient identification.
Moomaw also said payer access has reached broad parity, leaving product choice rather than coverage as the main commercial variable.
In Q&A, a Wells Fargo analyst asked about patient additions, while a LifeSci Capital analyst pressed on community penetration. Kaseta and Moomaw said current growth can continue, but did not commit to faster patient adds.
Liquidia Steps Up Pipeline Spending
Michael Kaseta pointed to $284.2 million of quarter-end cash and said second-half 2026 R&D expense is expected to double from the first half and rise again in 2027.
The CEO said Liquidia has 10 clinical studies underway or planned over the next 12 months across YUTREPIA and L606. He positioned L606's twice-daily dosing and tolerability profile as the next step in the franchise.
Chief medical officer Rajeev Saggar said a YUTREPIA study in progressive pulmonary fibrosis and idiopathic pulmonary fibrosis is planned for the first half of 2027. He also said RE-WARM is designed to inform a potential Phase III path in Raynaud's phenomenon.
LQDA Addresses Litigation and Adherence
A BTIG analyst asked about the pending 327 litigation. General Counsel Russell Schundler said outcomes remain unchanged, ranging from continued commercialization if Liquidia prevails to a royalty or injunctive relief if the ruling goes against the company.
Schundler also said that management lacks visibility into the judge's timing, while Roger Jeffs reiterated confidence in Liquidia's legal arguments and probability of success.
A BofA Securities analyst questioned adherence. Jeffs said Liquidia has no current concern about discontinuation rates and expects YUTREPIA's tolerability to support adherence, while noting that more time is needed for greater detail.
Liquidia Keeps Execution at the Center
The CEO framed the quarter around sustained adoption, growing inhaled-market share and continued clinical investment, with YUTREPIA funding a broader development agenda.
Kaseta's outlook paired continued revenue growth with higher R&D and SG&A spending while maintaining a goal of growing profitability. The operating focus remains commercial scale, pipeline expansion and the 2027 revenue objective.
What Zacks Signals Say About LQDA
LQDA sports a Zacks Rank #1 (Strong Buy), the highest rank in the system, which is designed around earnings-estimate revisions and near-term outperformance potential. Its Growth Score of A is the strongest of its style readings.
The Value Score of D, Momentum Score of F and VGM Score of C make the style picture mixed, since Zacks identifies an A or B Style Score as the strongest complements to Rank #1 or #2 stocks. The Zacks Rank can change as analyst estimates are revised following the just-reported results.
View the Zacks #1 Rank List
Image: Bigstock
LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue Path
Key Takeaways
Liquidia Corporation (LQDA - Free Report) used its Q2 2026 earnings call to reinforce a forward message centered on YUTREPIA adoption, commercial expansion and a path to more than $1 billion in net revenue in 2027.
Management also emphasized a broader inhaled-treprostinil strategy, pairing cash generation with a larger clinical program for YUTREPIA and L606. The Q&A focused on patient growth, payer access, community penetration and patent litigation.
LQDA Sets a 2027 Revenue Marker
Chief executive officer (CEO) Roger Jeffs said Liquidia is on track for more than $1 billion in net revenues in 2027, setting a longer-term benchmark for the franchise.
Chief operating officer and chief financial officer Michael Kaseta said referrals and new patient starts have followed a linear trajectory since launch and expressed confidence that the company can maintain that pace.
For Q2, EPS of $0.74 topped the Zacks Consensus Estimate of $0.7, while revenues of $171.7 million exceeded the $165.2 million consensus. Michael Kaseta said profitability should continue growing even as investment rises.
Liquidia Corporation Price, Consensus and EPS Surprise
Liquidia Corporation price-consensus-eps-surprise-chart | Liquidia Corporation Quote
Liquidia Sees YUTREPIA Taking Share
Roger Jeffs said YUTREPIA generated $170.4 million in Q2 net product sales, up 31% sequentially. As of July 31, Liquidia had about 5,900 unique patient prescriptions and more than 5,000 patient starts.
Jeffs added that the inhaled prostacyclin market grew from $573 million in Q1 to $607 million in Q2, while YUTREPIA approached 30% of that market on a net revenue basis.
The CEO tied the adoption to management's tolerability-dose-efficacy framework, arguing that higher tolerable dosing supports the company's confidence in continued uptake.
LQDA Broadens Commercial Reach
Chief commercial officer Scott Moomaw said the expanded sales force will increase contact with existing prescribers while pushing deeper into community settings, particularly for PH-ILD patient identification.
Moomaw also said payer access has reached broad parity, leaving product choice rather than coverage as the main commercial variable.
In Q&A, a Wells Fargo analyst asked about patient additions, while a LifeSci Capital analyst pressed on community penetration. Kaseta and Moomaw said current growth can continue, but did not commit to faster patient adds.
Liquidia Steps Up Pipeline Spending
Michael Kaseta pointed to $284.2 million of quarter-end cash and said second-half 2026 R&D expense is expected to double from the first half and rise again in 2027.
The CEO said Liquidia has 10 clinical studies underway or planned over the next 12 months across YUTREPIA and L606. He positioned L606's twice-daily dosing and tolerability profile as the next step in the franchise.
Chief medical officer Rajeev Saggar said a YUTREPIA study in progressive pulmonary fibrosis and idiopathic pulmonary fibrosis is planned for the first half of 2027. He also said RE-WARM is designed to inform a potential Phase III path in Raynaud's phenomenon.
LQDA Addresses Litigation and Adherence
A BTIG analyst asked about the pending 327 litigation. General Counsel Russell Schundler said outcomes remain unchanged, ranging from continued commercialization if Liquidia prevails to a royalty or injunctive relief if the ruling goes against the company.
Schundler also said that management lacks visibility into the judge's timing, while Roger Jeffs reiterated confidence in Liquidia's legal arguments and probability of success.
A BofA Securities analyst questioned adherence. Jeffs said Liquidia has no current concern about discontinuation rates and expects YUTREPIA's tolerability to support adherence, while noting that more time is needed for greater detail.
Liquidia Keeps Execution at the Center
The CEO framed the quarter around sustained adoption, growing inhaled-market share and continued clinical investment, with YUTREPIA funding a broader development agenda.
Kaseta's outlook paired continued revenue growth with higher R&D and SG&A spending while maintaining a goal of growing profitability. The operating focus remains commercial scale, pipeline expansion and the 2027 revenue objective.
What Zacks Signals Say About LQDA
LQDA sports a Zacks Rank #1 (Strong Buy), the highest rank in the system, which is designed around earnings-estimate revisions and near-term outperformance potential. Its Growth Score of A is the strongest of its style readings.
You can see the complete list of today’s Zacks #1 Rank stocks here.
The Value Score of D, Momentum Score of F and VGM Score of C make the style picture mixed, since Zacks identifies an A or B Style Score as the strongest complements to Rank #1 or #2 stocks. The Zacks Rank can change as analyst estimates are revised following the just-reported results.